Turning green gunk to gold, anti-cancer goldJanuary 10, 2007ANN ARBOR, Mich.-Combining synthetic chemistry techniques with a knowledge of the properties and actions of enzymes, scientists have been able to produce an exciting class of anti-cancer drugs originally isolated from blue-green algae. This accomplishment is expected to make it possible to produce enough of the promising drugs for use in clinical trials. In a study featured on the cover of the January issue of the journal ACS Chemical Biology, a scientific team lead by University of Michigan Life Sciences Institute Research Professor David H. Sherman and researcher Zachary Q. Beck found the trick to turning the green gunk into gold-cancer fighting gold. "It was simply too difficult to use the native blue-green algae for high-level production using traditional fermentation approaches," said Sherman. But the compound, called cryptophycin 1, held so much promise as an anti-cancer drug that organic chemists got busy trying to find ways to make a synthetic form of the compound in large enough quantities for clinical trials. Developing an efficient synthetic route to natural product compounds and their analogs is often an essential step in drug development. With drugs such as penicillin and tetracycline, it can easily be done, but cryptophycins present more of a challenge. Sherman's team realized that with all cryptophycins, the most difficult step came very late in the synthesis, at the point at which a key part called an epoxide-a highly strained, three-membered ring oxygen-containing group, crucial for the drug's anti-cancer activity-becomes attached to the molecule. The epoxide group can be attached in two configurations, designated as alpha and beta. Scientists have known for several years that the beta configuration was absolutely required for the anti-cancer properties of the drug, but were unable to devise efficient synthetic strategies that favored that configuration. Sherman's team accomplished this by isolating the entire set of biosynthetic genes and key enzymes and developing a new, efficient method to manufacture the broad class of cryptophycin natural products, including important analogs with clinical potential. This included characterization of an enzyme, cytochrome P450, that always introduces the epoxide in the desired beta configuration. Sherman, who is also the John G. Searle Professor of Medicinal Chemistry in the College of Pharmacy, believes that this approach will allow effective new cryptophycin analogs with low levels of side effects to be created for clinical trials. "This issue represented an exciting target that offered not only an interesting scientific problem, but the potential to do something of practical importance in creating a promising anti-cancer drug," he said. "Biosynthetic Characterization and Chemoenzymatic Assembly of the Cryptophycins. Potent Anticancer Agents from Nostoc Cyanobionts" by Magarvey N. A.; Beck Z. Q.; Golakoti T. ; Ding Y. ; Huber U. ; Hemscheidt T. K.; Abelson D. ; Moore R. E.; Sherman D. H. appeared online Dec.15 and is the cover story in the print version of ACS Chemical Biology January, 2007. The Regents of the University of Michigan |
|||||||||||||||||||||
| Related Anti-cancer Current Events and Anti-cancer News Articles Study shows further benefits of noscapine for prostate cancer New research has revealed a major breakthrough in the use of cough medicine ingredient noscapine as a prophylactic treatment for prostate cancer. New cancer drug screening technique more closely mirrors reality Improving on traditional screening tests for potential anti-cancer drugs, scientists at Dana-Farber Cancer Institute have developed a laboratory technique that more closely simulates the real-world conditions in which tumor cells mingle with the body's normal cells. Breast cancer drug fulvestrant appears more effective in the presence of CK8 and CK18 Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy. Designer nano luggage to carry drugs to diseased cells For the first time, scientists have succeeded in growing empty particles derived from a plant virus and have made them carry useful chemicals. Freezing breast tumors helps stop cancer's spread in mice, U-M study finds Freezing a cancer kills it in its place, and also appears to generate an immune response that helps stop the cancer's spread, leading to improved survival rates over surgery. Researchers fishing for cancer cure discover active DHA derivatives The next treatment for cancer might come from fish says a new research report published in the March 2010 print edition of the FASEB Journal. Bitter melon extract decreased breast cancer cell growth Bitter melon extract, a common dietary supplement, exerts a significant effect against breast cancer cell growth and may eventually become a chemopreventive agent against this form of cancer, according to results of a recent study. Oil droplets can navigate complex maze Call them oil droplets with a brain or even "chemo-rats." Scientists in Illinois have developed a way to make simple oil droplets "smart" enough to navigate through a complex maze almost like a trained lab rat. Shifting cellular energy metabolism may help treat cardiovascular disease Drugs that target the way cells convert nutrients into energy could offer new approaches to treating a range of conditions including heart attack and stroke. Researchers create drug to keep tumor growth switched off A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. More Anti-cancer Current Events and Anti-cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||